treatment of diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
All entries for: Lyell Immunopharma, Inc.
January 26, 2026
Lyell Immunopharma, Inc.
Orphan Drug Designation
South San Francisco, California
201-500 employees
Disease Area: Rare Disease
August 12, 2025
Lyell Immunopharma, Inc.
Neutral Outlook
South San Francisco, California
201-500 employees
Further, the Inflation Reduction Act of 2022 (the IRA), signed into law on August 16, 2022, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule